At the same time, systematic studies using human breast cancer cell lines demonstrated that licochalcone A, a natural compound, is a novel, reversible and selective, non-S-adenosyl L-methionine (SAM) binding site competitive PRMT6 inhibitor. The gene discussed is PRMT6; the disease is breast cancer.